Source comparison
BPC-157 TB-500 Post-Surgical Research: Protocol Comparison
Before committing to a specific peptide protocol, understanding the trade-offs between dosing regimens, administration routes, and timing windows is critical for experimental design. Primary Mechanism Nitric oxide preservation, angiogenesis, FAK-paxillin activ
This comparison does not assign a generated winner or score.
- Before committing to a specific peptide protocol, understanding the trade-offs between dosing regimens, administration routes, and timing windows is critical for experimental design.
- Primary Mechanism
- Nitric oxide preservation, angiogenesis, FAK-paxillin activation
- Actin sequestration, fibroblast migration, VEGF upregulation
- Dual mechanism: vascular protection + cellular migration
- Combined protocols show additive effects in tendon/ligament models but require precise timing to avoid overlapping inflammatory modulation
- Typical Dosing (animal model)
- 10–20 mcg/kg subcutaneous or IP
- 1–10 mg/kg IP or subcutaneous
- BPC-157 10 mcg/kg + TB-500 6 mg/kg
- Higher combined doses do not proportionally increase efficacy. Ceiling effects observed above standard ranges
- Administration Frequency
- Daily during acute phase (days 0–7)
- Twice weekly during proliferative phase (days 3–21)
- BPC-157 daily (days 0–7), TB-500 twice weekly (days 3–21)
- Staggered timing aligns with distinct healing phases. BPC-157 targets acute inflammation, TB-500 targets proliferation
- Onset of Measurable Effects
- Angiogenesis markers elevated by 48–72 hours
- Fibroblast infiltration increased by day 5–7
- Vascular integrity preserved early, collagen deposition accelerated mid-phase
- Combined protocols require week 2–3 histological analysis to capture full effect spectrum
- Cost per Protocol (research-grade)
- $80–$120 per 4-week model
- $150–$250 per 4-week model
- $230–$370 per 4-week model
- Cost scales with purity verification. Unverified peptides are cheaper but introduce uncontrolled variables